These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 2734533)

  • 21. Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence.
    Havrilesky LJ; Whitehead CM; Rubatt JM; Cheek RL; Groelke J; He Q; Malinowski DP; Fischer TJ; Berchuck A
    Gynecol Oncol; 2008 Sep; 110(3):374-82. PubMed ID: 18584856
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
    Silva EG; Gershenson DM; Malpica A; Deavers M
    Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Squamous cell carcinoma antigen in follow-up of cervical cancer treated with radiotherapy: evaluation of cost-effectiveness.
    Forni F; Ferrandina G; Deodato F; Macchia G; Morganti AG; Smaniotto D; Luzi S; D'Agostino G; Valentini V; Cellini N; Giardina B; Scambia G
    Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1145-9. PubMed ID: 17689030
    [TBL] [Abstract][Full Text] [Related]  

  • 24. LDH/L-lactate: NAD+ oxidoreductase (E.C.1.1.1.27) activity in the cystic fluid of benign and malignant ovarian tumours.
    Jandová A; Laurová L; Janousková M; Novotná J; Pezlarová J; Skoda V; Trnka V
    Acta Univ Carol Med Monogr; 1977; (78 Pt 2):121-3. PubMed ID: 615457
    [No Abstract]   [Full Text] [Related]  

  • 25. Labile disulfide bonds and free thiol groups in human IgG. V. Association of postoperative mean 'sigma S' course and tumor recurrence in ovarian cancer.
    Lahousen M; Schauenstein E; Reiter M; Estelberger W
    Wien Klin Wochenschr; 1989 Dec; 101(24):858-61. PubMed ID: 2623877
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The value of serum CA 125 for monitoring treatment of patients with ovarian cancer].
    Zaucha R; Kobierska A
    Przegl Lek; 1995; 52(2):51-3. PubMed ID: 7784616
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Salvage weekly paclitaxel in recurrent ovarian cancer.
    Abu-Rustum NR; Aghajanian C; Barakat RR; Fennelly D; Shapiro F; Spriggs D
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-62-S15-67. PubMed ID: 9346225
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current therapy for dysgerminoma of the ovary.
    Higgins R; Donaldson ES
    Obstet Gynecol; 1988 Feb; 71(2):287-8. PubMed ID: 3336569
    [No Abstract]   [Full Text] [Related]  

  • 29. [Immunodiagnostic studies in ovarian cancer using the leukocyte adherence inhibition test (LAI test). 2. Preoperative studies and follow-up].
    Ludwig HJ; Storch H
    Zentralbl Gynakol; 1986; 108(10):607-19. PubMed ID: 3526756
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The role of tumor marker CA 125 in the treatment of ovarian cancer].
    Porsbjerg CM; Sørensen JB; Lund BA
    Ugeskr Laeger; 1998 Feb; 160(7):995-1000. PubMed ID: 9477746
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ovarian cancer recurrences in patients with no macroscopic tumor at second-look laparotomy.
    Copeland LJ; Gershenson DM
    Obstet Gynecol; 1986 Dec; 68(6):873-4. PubMed ID: 3785802
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of integrated whole-body PET/CT in the detection of recurrent ovarian cancer.
    Hauth EA; Antoch G; Stattaus J; Kuehl H; Veit P; Bockisch A; Kimmig R; Forsting M
    Eur J Radiol; 2005 Nov; 56(2):263-8. PubMed ID: 16233894
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum CA-125 in relation to adnexal dysplasia and cancer in women at hereditary high risk of ovarian cancer.
    Hermsen BB; von Mensdorff-Pouilly S; Berkhof J; van Diest PJ; Gille JJ; Menko FH; Blankenstein MA; Kenemans P; Verheijen RH
    J Clin Oncol; 2007 Apr; 25(11):1383-9. PubMed ID: 17416858
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Digital rectal examination is no longer necessary in the routine follow-up of men with undetectable prostate specific antigen after radical prostatectomy: the implications for follow-up.
    Chaplin BJ; Wildhagen MF; Schroder FH; Kirkels WJ; Bangma CH
    Eur Urol; 2005 Dec; 48(6):906-10. PubMed ID: 16126322
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Cancer of the ovary: the usefulness of Cul-de-sac aspiration and the level of carcino-embryonic antigen in the peritoneal fluid].
    Zylberberg B; Salat-Baroux J; Ravina JH; Demarcourt V; Dormont D
    J Gynecol Obstet Biol Reprod (Paris); 1982; 11(3):365-70. PubMed ID: 7119382
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cancer of the ovary.
    Liu CM
    N Engl J Med; 2005 Mar; 352(12):1268-9; author reply 1268-9. PubMed ID: 15791705
    [No Abstract]   [Full Text] [Related]  

  • 37. Vascular endothelial growth factor levels in ovarian cyst fluid correlate with malignancy.
    Hazelton D; Nicosia RF; Nicosia SV
    Clin Cancer Res; 1999 Apr; 5(4):823-9. PubMed ID: 10213218
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthetic factor for evaluation of the effectiveness of the therapy in ovarian carcinoma.
    Dobryszycka W; Waszkiewicz L; Kuriata E; Peisert E; Gerber J; Ujec M
    Arch Immunol Ther Exp (Warsz); 1987; 35(5):623-9. PubMed ID: 3455651
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Abdominal recurrence of ovarian cancer: value of abdominal MR in patients with positive CA125 and negative CT.
    Balestreri L; Bison L; Sorio R; Morra A; Campagnutta E; Morassut S
    Radiol Med; 2002; 104(5-6):426-36. PubMed ID: 12589264
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ovarian cancer tumor marker behavior in asymptomatic healthy women: implications for screening.
    Crump C; McIntosh MW; Urban N; Anderson G; Karlan BY
    Cancer Epidemiol Biomarkers Prev; 2000 Oct; 9(10):1107-11. PubMed ID: 11045795
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.